Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more
Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, raised $318 million by offering 17.6 million shares at $18, the high end of the $16 to $18 range. The company had originally planned to offer 14.7 million...read more
Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $250 million by offering 14.7 million shares at a price...read more
Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, filed on Monday with the SEC to raise up to $100 million in an initial public offering. Lycia Therapeutics is developing therapeutics designed to degrade...read more
Renaissance Capital’s October IPO Market Update
Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more
Lycia Therapeutics prices upsized IPO at $18, the high end of the range
Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, raised $318 million by offering 17.6 million shares at $18, the high end of the $16 to $18 range. The company had originally planned to offer 14.7 million...read more
Allergy and autoimmune biotech Lycia Therapeutics sets terms for $250 million IPO
Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $250 million by offering 14.7 million shares at a price...read more
Lycia Therapeutics files for a $100 million IPO, targeting food allergies and autoimmune diseases
Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, filed on Monday with the SEC to raise up to $100 million in an initial public offering. Lycia Therapeutics is developing therapeutics designed to degrade...read more